|
|
作者：丁香园肿瘤时间
本文仅供中国大陆地区执业的医学药学专业人士参考，如您非前述专业人士，请离开本页面
✩ 本文仅供医疗卫生等专业人士参考
审批码：KIS0023584-58780，有效期至 2025-05-10，资料过期，视同作废
内容审核：唐颖
项目审核：文思宁
题图来源：图虫创意
参考文献
[1] Li J, et al. BMC Cancer, 2011, 11:364.
[2] Tjokrowidjaja A, Lee CK, Houssami N, et al. Metastatic breast cancer in young women: a population-based cohort study to describe risk and prognosis. Intern Med J. 2014 Aug;44(8):764-70.
[3] Huppert LA, et al. CA Cancer J Clin. 2023 Sep-Oct;73(5):480-515.
[4] Li Y, et al. The Breast, 2022, 61:129⁃135.
[5] 中国年轻乳腺癌诊疗专家共识(2022).
[6] 中国晚期乳腺癌规范诊疗指南(2022).
[7] NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. 2023v4.
[8] CDK4/6抑制剂治疗激素受体阳性人表皮生长因子受体2阴性晚期乳腺癌的临床应用共识(2023).
[9] Debu Tripathy, et al. Lancet Oncol . 2018 Jul;19(7):904-915.
[10] Yen-Shen Lu, et al. Clin Cancer Res . 2022 Mar 1;28(5):851-859.
[11] Y. Lu, et al. ESMO Asia Virtual Congress 2020. 47MO.
[12] https://www.esmo.org/mo-mcbs/esmo-mcbs-score-cards/scorecard-158-1.[MONALEESA-7]
[13] 2022 ESMO ASIA: 21MO.
[14] Hurvitz SA et al. ESMO 2020; Abstract 276O
[15] Harbeck N, et al. Ther Adv Med Oncol. 2020 Jul 26;12:1758835920943065.
[16] Wang R, Zhu Y, Liu X, et al. The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer. BMC Cancer. 2019;19(1):1091.
[17] Harb WA. Management of patients with hormone receptor-positive breast cancer with visceral disease: challenges and treatment options. Cancer Manag Res. 2015;7:37-46.
[18] D.A. Yardley, Y.S. Yap, H.A. Azim, et al. Pooled exploratory analysis of survival in patients (pts) with HR+/HER2- advanced breast cancer (ABC) and visceral metastases (mets) treated with ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA (ML) trials. ESMO 2022. Poster 205P.
[19] Lu YS, Im SA, Colleoni M, et al. Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial. Clin Cancer Res. 2022;28(5):851-859.
[20] Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. N Engl J Med. 2022;386(10):942-950.
[21] Johnson RH, et al. JAMA. 2013;309(8):800-805.
[22] Chen, Z, et al. Front Oncol. 2022 Mar 3;12:829693
[23]《国家医保局2023年国家基本医疗保险､工伤保险和生育保险药品目录调整新闻发布会实录》｡引用自http://www.nhsa.gov.cn/art/2023/12/13/art_14_11684.html
[24] Jacquet, E., et al., Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients. Eur J Cancer, 2018. 95: p. 93-101.
[25] Twelves, C., et al., Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer: retrospective analysis from Leeds Cancer Centre. BMC Cancer, 2020. 20(1): p. 53.
|
|
